Alex Kalomparis, Gilead senior VP of public affairs
September 19, 2023 11:13 AM EDTUpdated 02:45 PM
Pharma
Marketing

Q&A: Gilead pub­lic af­fairs chief on new strat­e­gy, Tik­Tok, and why the com­pa­ny won’t ‘keep do­ing things the same way’ 

Beth Snyder Bulik

Senior Editor

Af­ter years of qui­et fo­cus on HIV and vi­rol­o­gy and sto­ic re­spons­es to flare-ups of at­ten­tion over its pric­ing de­ci­sions, the new Gilead Sci­ences is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times